ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand physician treatment decisions in selecting
specific second line treatments in pediatric ITP and to determine the effectiveness of
different second line ITP treatments. Eligible patients are those ages 1-18 years who are
starting on a new second line treatment for ITP, defined as any treatment other than IVIG,
steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for
approximately one year.
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital